Harnessing the microbiome to transform lives

Harnessing the
microbiome
to transform lives

Corporate profile

Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery platform to develop a novel class of orally administered biological drugs.

With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for recurrent C. difficile infection (CDI). In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch is also developing CP101 for chronic hepatitis B, and FIN-211 for autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for ulcerative colitis and Crohn’s disease, respectively.

Press releases

Finch Therapeutics to Present at Upcoming Virtual Investor Conferences
May 28, 2021
Finch Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Updates
May 13, 2021
Finch Therapeutics to Participate in the BofA Securities 2021 Virtual Health Care Conference
May 6, 2021

Upcoming events

The JMP Securities Life Sciences Conference

Jun 17, 2021 | 1:30 PM EDT
Latest presentation
Corporate Presentation – June 2021